Cardiology – Page 27

Redefining Iron Deficiency in Heart Failure: Why TSAT and Serum Iron Outperform Ferritin for Prognosis

By MedXY 12/26/2025

Recent large-scale studies, including HEART-FID and major national registries, demonstrate that transferrin saturation (TSAT) and serum iron levels are more accurate predictors of functional capacity and mortality in heart failure than traditional ferritin-based definitions.

Cardiology Family Medicine & Nutrition news

Beyond Sodium Restriction: Legumes and Vegetables Linked to Improved Outcomes in Heart Failure

By MedXY 12/26/2025

A substudy of the global G-CHF registry demonstrates that higher intake of legumes and vegetables significantly reduces the risk of death and hospitalization in heart failure patients, while refined grains increase risk, highlighting the importance of food quality over simple nutrient restriction.

Cardiology Nephrology news

Empagliflozin Enhances Cardiovascular Protection in HFrEF Patients with Low Serum Magnesium: Evidence from EMPEROR-Reduced

By MedXY 12/26/2025

This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electrolyte-stabilizing benefit of SGLT2 inhibitors.

Cardiology news

PDE9 Inhibition with CRD-740 Safely Elevates cGMP Levels in HFrEF: Results from the CARDINAL-HF Trial

By MedXY 12/26/2025

The Phase 2 CARDINAL-HF trial demonstrates that CRD-740, a novel PDE9 inhibitor, significantly increases plasma and urinary cGMP in patients with heart failure and reduced ejection fraction. The treatment was well tolerated and effective even alongside sacubitril/valsartan, suggesting a potential new therapeutic pathway.

Cardiology Diabetes & Endocrinology news

Elevated Natriuretic Peptides: A Potent Predictor of Heart Failure and Mortality in Asymptomatic Diabetes

By MedXY 12/26/2025

A large-scale cohort study demonstrates that screening natriuretic peptide levels in individuals with type 1 or type 2 diabetes significantly predicts incident heart failure and death, advocating for routine biomarker-based risk stratification in this high-risk population.

Cardiology Internal Medicine news

Beyond the Scale: Abdominal Adiposity Outperforms BMI in Predicting Outcomes for HFpEF and HFmrEF

By MedXY 12/26/2025

A pooled analysis of 21,479 HFpEF/HFmrEF patients reveals that waist-to-height ratio is a superior, linear predictor of mortality and heart failure events compared to BMI. Even in non-obese BMI categories, nearly 90% of patients exhibit excess abdominal adiposity, necessitating a shift in clinical assessment.

Cardiology Internal Medicine news

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

By MedXY 12/26/2025

A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial eligibility cutoffs.

Cardiology Diabetes & Endocrinology news

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

By MedXY 12/26/2025

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated or stable/decreasing NT-proBNP, supporting a biomarker-guided approach to prevention.

Cardiology news Pediatrics

Cardiac Progenitor Cells in Hypoplastic Left Heart Syndrome: Safety Established, but Efficacy Remains Elusive in the CHILD Trial

By MedXY 12/26/2025

The Phase I CHILD trial demonstrates that intramyocardial injection of neonatal cardiac progenitor cells during HLHS palliation is safe but does not improve right ventricular function at one year, despite promising signals in secondary clinical outcomes.

Cardiology Clinical Updates news

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial

By MedXY 12/26/2025

This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone's efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity, and chronic obstructive pulmonary disease.

Cardiology news

Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial

By MedXY 12/26/2025

This analysis of the FINEARTS-HF trial identifies that while finerenone increases hypotension risk in HFmrEF and HFpEF patients, its clinical benefits persist. The study highlights key predictors of hypotension, such as low baseline blood pressure and advanced age, emphasizing the need for vigilant clinical monitoring.

Cardiology news

Nanosecond Pulsed Field Ablation Matches Radiofrequency Efficacy While Slashing Procedure Time: Insights From the InsightPFA Trial

By MedXY 12/26/2025

The InsightPFA trial confirms that a novel nanosecond pulsed field ablation (nsPFA) system is noninferior to radiofrequency ablation for paroxysmal atrial fibrillation, significantly reducing procedure and left atrial dwell times while maintaining a comparable safety profile.

Cardiology news

Beyond Beta-Blockers: Aficamten Reinvents First-Line Therapy for Obstructive Hypertrophic Cardiomyopathy

By MedXY 12/25/2025

The MAPLE-HCM trial demonstrates that aficamten monotherapy provides superior, rapid, and comprehensive clinical benefits compared to the traditional first-line treatment, metoprolol, across multiple disease domains in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiology Clinical Updates news

Comparative Efficacy, Safety, and Complications of Subcutaneous Versus Transvenous Implantable Cardioverter-Defibrillators: Insights from the PRAETORIAN and ATLAS Trials and Meta-Analyses

By MedXY 12/25/2025

This review synthesizes randomized trial data comparing subcutaneous and transvenous ICDs, highlighting differences in inappropriate shocks, device-related complications, and shock efficacy, underscoring clinical considerations for ICD selection.

Cardiology Internal Medicine news

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

By MedXY 12/25/2025

A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI above 35 kg/m2, emphasizing a targeted therapeutic advantage for this high-risk population.

Cardiology news Public Health

Statin Initiation and Follow-Up Testing Are Declining in Young Adults Despite High Cardiovascular Risk

By MedXY 12/25/2025

A large-scale study of over 700,000 young adults reveals a concerning decline in lipid follow-up and statin initiation between 2008 and 2018, highlighting a critical care gap in preventing premature cardiovascular disease during a key window of vulnerability.

Cardiology news

Myval THV Demonstrates 1-Year Noninferiority to Established Transcatheter Heart Valves: Insights from the LANDMARK Trial

By MedXY 12/25/2025

The LANDMARK trial reports that the novel Myval balloon-expandable transcatheter heart valve is clinically noninferior to contemporary SAPIEN and Evolut series at one year, offering comparable safety, hemodynamic performance, and quality-of-life improvements for patients with severe aortic stenosis.

Cardiology news

Pulsed Field Ablation Demonstrates Exceptional Safety in Real-World Practice: Insights from the 40,000-Patient MANIFEST-US Study

By MedXY 12/25/2025

The MANIFEST-US study of over 40,000 patients confirms that pulsed field ablation (PFA) for atrial fibrillation maintains a high safety profile in real-world U.S. clinical practice, with a major complication rate of just 0.63% and a complete absence of esophageal fistulas or pulmonary vein stenosis.

Cardiology Infectious Diseases news

Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial

By MedXY 12/25/2025

The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio suggest biological activity and safety in this neglected population.

Cardiology Neurology news

Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study

By MedXY 12/25/2025

The Hamburg City Health Study reveals that elevated NT-proBNP and hs-cTnI are significantly linked to neurodegeneration and vascular brain injury. These cardiac biomarkers offer a non-invasive pathway for identifying patients at high risk for cognitive impairment and structural brain changes.